CJMB: Callan JMB Inc Long-Term Debt Volume

This price chart illustrates the performance of Callan JMB Inc (CJMB), whose operating income stands at 0.00, with a business model relying on government procurement for clinics and patent protection. A staff of dedicated engineers, driven by the high significance of their work, ensures the development of complex systems. Consequently, Callan JMB Inc (CJMB) dominates the traumatology niche, creating ultra-precise instruments for limb salvage in cases of critical injury.

CJMB Callan JMB Inc.: Company Long-Term Debts in the range 02/06/2025 - 10/28/2026

Analytical breakdowns for Callan JMB Inc

- price and consensus price forecast:
Share Price Callan JMB Inc.|CJMB - Analyst Consensus Forecast
- market capitalization data:
Market Capitalization Callan JMB|CJMB - Enterprise Value
- book capitalization data:
Accounting Value per Share Callan JMB|CJMB - Book Capitalization|Market Capitalization to Book Value Ratio callanjmb.com|CJMB - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity Callan JMB Inc|CJMB - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Callan JMB Inc.|CJMB - Company Aggregate Debts|Debts to Net Assets Callan JMB|CJMB - Company Long-Term Debt|Company Short-Term Indebtedness Callan JMB
General company analysis:Callan JMB Inc (CJMB)

For Callan JMB Inc (CJMB), long-term liabilities reflect a financing strategy aimed at expansion within the medtech sector. This metric aggregates all creditor obligations with maturities exceeding one year, measuring the debt load relative to equity. By analyzing the company's long-term debt value, an investor assesses the balance between leveraged capital and the pace of distribution scaling. A reduction in debt confirms financial autonomy, whereas growth indicates investments in new products. Stable dynamics of this indicator guarantee business resilience during the expansion of the solutions portfolio.

Competitor analysis

Company Long-Term Indebtedness intuitive.com ISRG|Company Long-Term Debts DHR (Danaher)|BDX - Long-Term Debt Volume|STE (STERIS Corporation) - Company Long-Term Debts|West Pharma Corp (WST) - Company Long-Term Liabilities|BAX (Baxter International) - Company Long-Term Debts|Company Long-Term Debts MASI|Company Long-Term Debt Stevanato Group (STVN)|Company Long-Term Debt Teleflex Inc. TFX|Company Long-Term Liabilities Merit Medical Systems Inc|Company Long-Term Loans and Borrowings Nobel Biocare NVST|Company Long-Term Debts ICUI (ICU Medical, Inc.)|XRAY: Long-Term Debt Volume|Company Long-Term Debt LeMaitre Vascular|ATRC (AtriCure Inc) - Company Long-Term Indebtedness|STAA: Company Long-Term Debt|Long-Term Debt Volume niagenbioscience.com (NAGE)|Company Long-Term Liabilities ZimVie Inc.|Amount of Long-Term Liabilities ANGO (angiodynamics.com)|Company Long-Term Debt Cerus|TKNO - Company Long-Term Loans and Borrowings|Monogram Technologies Inc - Company Long-Term Liabilities|STSS: Company Long-Term Debts|INFU (infusystem.com) - Company Long-Term Debt|utahmed.com (UTMD) - Company Long-Term Liabilities|Company Long-Term Debts KRMD (KORU Medical Systems, Inc.)|Long-Term Debt NYXH|Company Long-Term Debt Microbot Medical Inc MBOT|Company Long-Term Indebtedness Pro-Dex Inc. PDEX|Company Long-Term Liabilities Zentek Ltd. (ZTEK)|elutia.com - Amount of Long-Term Liabilities|Company Long-Term Debt MLSS (Milestone Scientific Inc.)|NXGL - Long-Term Debt Volume|RVP (retractable.com) - Company Long-Term Debts|Harvard Bioscience Inc. (HBIO) - Company Long-Term Liabilities|FEMY (Femasys Inc.) - Company Long-Term Debts|Company Long-Term Debts MHUA|Company Long-Term Debt Predictive Oncology (POAI)|Company Long-Term Debt ATRI (Atrion Corp.)|Company Long-Term Debt NeuroMetrix Corp NURO